Why Is INSMED INC (INSM) Stock Up Today?

Insmed shares rose 15.06% to $111.59 on Thursday, driven by a strong third-quarter revenue beat and raised full-year guidance. The stock’s surge followed the company’s announcement that Brinsupri revenue reached $400.1 million, contributing to a 268% year-over-year increase in total sales.

What Happened

Insmed reported third-quarter 2026 results with revenue of $524.428 million, exceeding the consensus estimate of $501.350 million. The company also provided a business update indicating that Brinsupri has achieved blockbuster status, with year-to-date revenue topping $1 billion. While the firm reported an EPS of $0.46, which missed the consensus estimate of $0.38, the market focused on the top-line growth and the upward revision to 2025 guidance for both Brinsupri and Arikayce.

Analyst reactions were mixed but generally positive regarding the growth trajectory. Stifel cut its price target to $195 citing operating expense outlook concerns, while Roth Capital raised its target to $204 from $198. The earnings call highlighted the significant momentum in the Brinsupri franchise, which was the primary catalyst for the share price appreciation.

What The Data Shows

The stock’s move aligns with a broader positive trend, having gained 18.4% over the last eight sessions. On the day of the announcement, the stock printed 17 fresh 52-week highs and two fresh 52-week lows. Fundamentals show the company remains unprofitable with a trailing twelve-month EPS of $4.09 and a net margin of $76.9%, but revenue growth stands at 185.8% year-over-year. The market cap is currently $20.7 billion.

Insider activity over the last 90 days has been dominated by selling, with four sales totaling $39.2 million and no buys. Notable sellers include Director David R. Brennan, Director Melvin Md Sharoky, and COO Roger Adsett. Congressional filings show one buy and one sell in the same period, with the most recent filing dated September 22, 2026.

What To Watch

Investors will monitor the company’s ability to sustain Brinsupri’s growth trajectory and manage operating expenses as it scales. The upcoming earnings date for the next quarter will be a key milestone for validating the raised guidance.